What are the big events to look for next year?

Novartis' ($NVS) Sandoz unit was the first to get a biosimilar approved in the U.S. with Zarxio, its copy of Amgen's ($AMGN) Neupogen, setting off what will be a significant development for the U.S. market as more copies of expensive biologics test the market. Many companies have built facilities with biosimilars in mind. But there were other significant events in 2015, huge M&A deals, and the ongoing uproar from consumers, payers, physicians and lawmakers over how drugmakers have been testing the limits drug pricing. Read about all of the most important developments of the year in FiercePharma. Report

 

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.